NEW TUMOUR MARKERS AND BIOLOGICAL APPLICATIONS THEREOF

摘要

The application relates to the use of at least one protein selected from the group consisting of FADD proteins and phosphorylated p38-MAPK, as a marker for absence of in vivo tumour. This use may further be complemented by the use of the FasL protein as a marker for presence of in vivo tumour. The (respective) amount(s) of FADD proteins and phosphorylated p38-MAPK indeed decrease, sometimes up to zero, with tumour development, while FasL expression is gained. FADD proteins are secreted from out of the tumour cells into their extracellular environment. A low cellular amount and a high extracellular amount of FADD proteins are prognostic of resistance to chemotherapy.